Xolair, a drug developed 15 years ago by Roche and Novartis, received a breakthrough designation from the US regulator in a new food allergy indication.
Xolair has gained EU approval as the first ever add-on therapy to treat chronic spontaneous urticaria (CSU) in adult and adolescent patients with inadequate response to H1-antihistamine tre
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<